Brokerages expect CorMedix Inc (NASDAQ:CRMD) to post $190,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for CorMedix’s earnings. The highest sales estimate is $300,000.00 and the lowest is $80,000.00. CorMedix reported sales of $370,000.00 during the same quarter last year, which would suggest a negative year-over-year growth rate of 48.6%. The business is scheduled to issue its next quarterly earnings report on Wednesday, November 13th.
According to Zacks, analysts expect that CorMedix will report full-year sales of $460,000.00 for the current financial year, with estimates ranging from $430,000.00 to $490,000.00. For the next fiscal year, analysts expect that the business will post sales of $12.28 million, with estimates ranging from $9.89 million to $14.67 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover CorMedix.
CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02). The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.13 million.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Recommended Story: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.